

SWIXX AND NORGINE SIGN DEAL ON ANGUSTA® FOR CEE

SWIXX ANNOUNCEMENT NO. 32

September 3rd, 2020

Baar, Switzerland – Swixx BioPharma AG announced today the signing of a Distribution Agreement with Norgine B.V., a leading European specialist pharmaceutical company headquartered in the Netherlands. The agreement gives Swixx the right to commercialize Norgine’s ANGUSTA® (misoprostol) across Central and Eastern Europe, including the EU countries of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia and the W. Balkan countries of Albania, Bosnia & Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia - where regulatory filings of Angusta are in preparation.

“It’s a great pleasure to announce this new contract,” commented Swixx CEO Jean-Michel Lespinasse. Angusta® brings a much-needed alternative for expecting mothers and healthcare professionals by providing a proven, safe oral treatment when induction of labour is required. We are pleased that Norgine has expressed confidence in Swixx to expand our cooperation beyond Plenvu® and Moviprep® to include Angusta®, thereby reinforcing the Swixx offering in both Gynaecology and Obstetrics. We would also like to take this opportunity to recognize and thank the Azanta team – our BD team had been negotiating this contract with Azanta prior to its acquisition by Norgine, and we have appreciated the opportunity to get to know and work with our excellent Azanta counterparts in Copenhagen.”

About Norgine

Norgine incorporated ANGUSTA® into its product portfolio following its acquisition of Azanta A/S in March 2020.

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 22 million patients around the world in 2019 and generated €419 million in net product sales, a growth of 6% over 2018.

Norgine has a direct presence in 14 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

In 2012, Norgine established Norgine Ventures, a complementary business which supports innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.

contact@norgine.com

www.norgine.com

Follow us @Norgine

About Swixx BioPharma AG

Swixx now operates fully owned subsidiaries across Central and Eastern Europe, offering coverage from Moscow to Prague and from Tallinn to Sofia. Net sales in 2019 were 143 million Euros and in 2020 should reach 220 million Euros. Established in 2014, Swixx has gathered outstanding specialty pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. The company specializes in representing research-based pharmaceutical, biotech, orphan, medical equipment and self-care brands.

For more information, please visit: www.swixxbiopharma.com

About ANGUSTA® (misoprostol)

ANGUSTA® (misoprostol 25 mcg) is indicated for the induction of labour. It is administered after careful assessment of the uterine cervix. ^[1]

Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1), a naturally occurring compound. Prostaglandins of the F and E series have been shown to increase mammalian collagenase activity and to cause cervical ripening and uterine contraction. ^[1]

ANGUSTA® is taken orally with a glass of water and the recommended dosing regimen is either 25 micrograms every two hours or 50 micrograms orally every four hours according to hospital practice. The maximum dose is 200 micrograms over a period of 24 hours. ^[1]

ANGUSTA® is administered by trained obstetric personnel in a hospital setting where facilities for continuous foetal and uterine monitoring are available. ^[1]

ANGUSTA® can cause excessive uterine stimulation and if this continues, dosing is stopped and treatment according to local guidelines commenced. ^[1]

ANGUSTA® is a product recently acquired by Norgine Pharmaceuticals and has been licensed in the Nordics, France and 10 other Central and Eastern European (CEE) countries since 2017.

About Induction of Labour

Induction of labour is defined by the World Health Organisation (WHO) as the process of artificially stimulating the uterus to start labour. There are a number of methods to achieve this and may include pharmacological treatment such as administering prostaglandins or oxytocin or by manually rupturing the amniotic membranes. ^[2]

There are a number of circumstances where the considered risk to foetal or maternal health outweigh the wait for spontaneous labour. These may include gestational age of 41 completed weeks or more, pre-labour rupture of amniotic membranes, hypertensive disorders, maternal medical complications and foetal death among others. Each case is considered on its own merit. ^[2]

Induction of labour, may cause discomfort due to the procedure itself and due to the woman's restricted mobility. To avoid any potential risks, the woman and her baby should be monitored closely. [2]

Endnotes:

1] ANGUSTA® Summary of Product Characteristics (SmPC). Available at: https://mri.cts-mrp.eu/Human/Downloads/DK_H_2584_001_FinalSPC.pdf Accessed August 2020

[2] WHO Recommendations for Induction of Labour 2011, WHO Press, World Health1]

Contact:

Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

Note on Unsubscribing from Swixx Announcement Mailing List: *In accordance with the European Union's GDPR (General Data Protection Regulation) provisos, should you wish to unsubscribe / opt out of our mailing list, please send to Maja.Boskovic@swixxbiopharma.com a one-line message "Please unsubscribe me."*